Stockreport

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Notable responses were also seen in patients with liver metastases, who often face poorer outcomes with this disease RARITAN, N.J. Jan. 10, 2026 /PRNewswire/ -- Johns [Read more]